Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients

References

• Leach DA, Mohr A, Giotis ES, Cil E, Isac AM, Yates LL, et al. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Nat Commun. 2021;12(1):4068. doi:10.1038/s41467-021-24342-y.
   PubMed Web of Science ®Google Scholar
• Mahoney M, Damalanka VC, Tartell MA, Chung D. h, Lourenço AL, Pwee D, et al. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proc Natl Acad Sci USA. 2021;118(43):e2108728118. doi: 10.1073/pnas.2108728118.
   PubMed Web of Science ®Google Scholar
• Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, HCA Lung Biological Network, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016–1035.e1019. doi:10.1016/j.cell.2020.04.035.
   PubMed Web of Science ®Google Scholar
• Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov. 2020;10(6):779–782. doi:10.1158/2159-8290.Cd-20-0451.
   PubMed Web of Science ®Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–1503. doi:10.1158/0008-5472.Can-11-3948.
   PubMed Web of Science ®Google Scholar
• Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, et al. The early effects of rapid androgen deprivation on human prostate cancer. Eur Urol. 2016;70(2):214–218. doi:10.1016/j.eururo.2015.10.042.
   PubMed Web of Science ®Google Scholar
• Qiao Y, Wang XM, Mannan R, Pitchiaya S, Zhang Y, Wotring JW, et al. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2. Proc Natl Acad Sci USA. 2020;118:20201211. doi:10.1073/pnas.2021450118.
   Web of Science ®Google Scholar
• Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27. doi:10.1097/00005650-199801000-00004.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang X, Li X, Xi D, Mao R, Wu X, et al. Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients. Cell Mol Immunol. 2020;17(8):878–880. doi:10.1038/s41423-020-0484-x.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi:10.1172/JCI137244.
   PubMed Web of Science ®Google Scholar
• Klein EA, Li J, Milinovich A, Schold JD, Sharifi N, Kattan MW, et al. Androgen deprivation therapy in men with prostate cancer does not affect risk of infection with SARS-CoV-2. J Urol. 2021;205(2):441–443. doi: 10.1097/JU.0000000000001338.
   PubMed Web of Science ®Google Scholar
• Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020;31(8):1040–1045. doi:10.1016/j.annonc.2020.04.479.
   PubMed Web of Science ®Google Scholar
• Tucker MD, Schmidt AL, Hsu C-Y, Shyr Y, Armstrong AJ, Bakouny Z, CCC19 Prostate Cancer Working Group, et al. Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT). JCO. 2021;39(6_suppl):39–39. doi:10.1200/JCO.2021.39.6_suppl.39.
   Web of Science ®Google Scholar
• Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu C-Y, Shyr Y, et al. Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19. JAMA Netw Open. 2021;4(11):e2134330. doi:10.1001/jamanetworkopen.2021.34330.
   PubMed Web of Science ®Google Scholar
• Karimi A, Nowroozi A, Alilou S, et al. Effects of androgen deprivation therapy on COVID-19 in patients with prostate cancer: a systematic review and meta-analysis. Urol J. 2021;18(6):577–584. doi:10.22037/uj.v18i.6691.
   PubMed Web of Science ®Google Scholar
• Shah NJ, Patel VG, Zhong X, et al. The impact of androgen deprivation therapy on COVID-19 illness in men with prostate cancer. JNCI Cancer Spectr. 2022;6:pkac035. doi:10.1093/jncics/pkac035.
   PubMed Web of Science ®Google Scholar
• Duarte MBO, Leal F, Argenton JLP, Carvalheira JBC. Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis. Infect Agent Cancer. 2021;16(1):66. doi:10.1186/s13027-021-00406-y.
   PubMed Web of Science ®Google Scholar
• Cadegiani FA, McCoy J, Gustavo Wambier C, Goren A. Early antiandrogen therapy with dutasteride reduces viral shedding, inflammatory responses, and time-to-remission in males With COVID-19: a randomized, double-blind, placebo-controlled interventional trial (EAT-DUTA AndroCoV trial - biochemical). Cureus. 2021;13(2):e13047. doi:10.7759/cureus.13047.
   PubMed Web of Science ®Google Scholar
• Lyon M, Li J, Cullen J, Milinovich A, Kattan M, Jehi L, et al. 5α-Reductase inhibitors are associated with reduced risk of SARS-CoV-2 infection: a matched-pair, registry-based analysis. J Urol. 2022;207(1):183–189. doi: 10.1097/JU.0000000000002180.
   PubMed Web of Science ®Google Scholar
• Cadegiani FA, Zimerman RA, Fonseca DN, Correia MN, Muller MP, Bet DL, et al. Final results of a randomized, placebo-controlled, two-arm, parallel clinical trial of proxalutamide for hospitalized COVID-19 patients: a multiregional, joint analysis of the proxa-rescue AndroCoV trial. Cureus. 2021;13(12):e20691. doi:10.7759/cureus.20691.
   PubMed Web of Science ®Google Scholar
• Welén K, Rosendal E, Gisslén M, Lenman A, Freyhult E, Fonseca-Rodríguez O, et al. A phase 2 trial of the effect of antiandrogen therapy on COVID-19 outcome: no evidence of benefit, supported by epidemiology and in vitro data. Eur Urol. 2022;81(3):285–293. 20211215. doi:10.1016/j.eururo.2021.12.013.
   PubMed Web of Science ®Google Scholar
• Nickols NG, Mi Z, DeMatt E, Biswas K, Clise CE, Huggins JT, et al. Effect of androgen suppression on clinical outcomes in hospitalized men with COVID-19: The HITCH randomized clinical trial. JAMA Netw Open. 2022;5(4):e227852-e227852. doi:10.1001/jamanetworkopen.2022.7852.
   Web of Science ®Google Scholar
• Cadegiani FA, McCoy J, Gustavo Wambier C, Vaño-Galván S, Shapiro J, Tosti A, et al. Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: results from a randomized, double-blinded, placebo-controlled trial. Cureus. 2021;13(2):e13492. doi:10.7759/cureus.13492.
   PubMed Web of Science ®Google Scholar
• De Giorgi A, Fabbian F, Greco S, Di Simone E, De Giorgio R, Passaro A, OUTcome and COMorbidity Evaluation of INTernal MEDicine COVID19 (OUTCOME-INTMED-COV19) Study Collaborators, et al. Prediction of in-hospital mortality of patients with SARS-CoV-2 infection by comorbidity indexes: an Italian internal medicine single center study. Eur Rev Med Pharmacol Sci. 2020;24(19):10258–10266. doi:10.26355/eurrev_202010_23250.
   PubMed Web of Science ®Google Scholar
• Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw Open. 2020;3(12):e2029058–e2029058. doi:10.1001/jamanetworkopen.2020.29058.
   PubMed Web of Science ®Google Scholar